Lipocine Inc. (NASDAQ:LPCN) reported that Chief Executive Officer Mahesh V. Patel purchased 25,000 shares of the company’s common stock on April 6, 2026. The shares were acquired at $2.03 per share, for a total outlay of $50,749.
The purchase comes as Lipocine’s stock is trading near its 52-week low of $1.81, after a sharp 74% decline during the prior week. Following the April 6 transaction, Patel now directly holds 160,679 shares of Lipocine common stock.
Market commentary included an InvestingPro analysis noting that the stock appears undervalued at current levels. The analysis referenced additional platform resources, including 15 extra ProTips and detailed financial metrics available to subscribers seeking further context on valuation and fundamentals.
In clinical program news, Lipocine announced that its postpartum depression candidate, LPCN 1154, did not achieve the primary endpoint in a phase 3 trial. The study enrolled 90 patients and failed to show a statistically significant reduction in depression scores relative to placebo.
Despite the lack of efficacy on the primary endpoint, Lipocine reported a favorable safety profile for LPCN 1154. According to the company, adverse events observed in the trial were characterized as mild to moderate. The phase 3 study was conducted entirely in an outpatient setting. Lipocine also noted that a scheduled independent safety review found no serious drug-related adverse events, and the trial continued without modifications following that review.
Following completion of patient enrollment and dosing in the phase 3 program, H.C. Wainwright revised its valuation view by raising its price target for Lipocine to $15 while maintaining a Buy rating. The firm’s analysts highlighted the progress represented by completing enrollment and dosing as a constructive development, even in light of the trial result.
These items together - insider buying at levels near the stock's 52-week low and the mixed clinical readout for LPCN 1154 - represent concurrent developments in Lipocine’s efforts to advance its postpartum depression treatment. The company’s clinical update and the CEO’s purchase were disclosed independently and provide investors with both operational and insider-transaction information to evaluate.